A randomized phase ii study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, fallopian tube or primary peritoneal carcinomas: The DoCaCel study

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2896-2902

  Reyners, A K L ^a   de Munck, L ^b   Erdkamp, F L G ^c   Smit, W M ^d   Hoekman, K ^e   Lalisang, R I ^f   de Graaf, H ^g   Wymenga, A N M ^d   Polee, M ^g   Hollema, H ^a   van Vugt, M A T M ^a   Schaapveld, M ^h   Willemse, P H B ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Netherlands Comprehensive Cancer Organisation The Netherlands   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MEDICAL CENTER LEEUWARDEN   (Netherlands)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Carboplatin; Celecoxib; Docetaxel; Epithelial ovarian cancer; First line chemotherapy; Randomized phase II study

Indexed keywords

EID: 84868138680     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds107     Document Type: Article

References (29)

1. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78: 1479-1487.
2. Aravantinos G, Fountzilas G, Bamias A et al. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer 2008; 44: 2169-2177.
3. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425.
4. Du Bois A, Weber B, Rochon J et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006; 24: 1127-1135.
5. Fairfield KM, Hunter DJ, Fuchs CS et al. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 535-542.
6. Menczer J. Cox-2 expression in ovarian malignancies: a review of the clinical aspects. Eur J Obstet Gynecol Reprod Biol 2009; 146: 129-132.
7. Steffensen KD, Waldstrom M, Jeppesen U et al. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17: 798-807.
8. Athanassiadou P, Grapsa D, Athanassiades P et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 2008; 204: 241-249.
9. Olsen SR. Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. Biomed Pharmacother 2005; 59: S306-S310.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
11. Vasey PA, Atkinson R, Coleman R et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001; 84: 170-178.
12. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
13. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884.
14. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
15. Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551.
16. Edelman MJ, Watson D, Wang X et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy. Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008; 26: 848-855.
17. Legge F, Paglia A, D'Asta M et al. Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients. BMC Cancer 2011; 11: 214.
18. Altorki NK, Keresztes RS, Port JL et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003; 21: 2645-2650.
19. Altorki NK, Christos P, Port JL et al. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol 2011; 6: 1121-1127.
20. Pierga J-Y, Delaloge S, Espié M et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010; 122: 429-437.
21. Lilenbaum R, Socinski MA, Altorki NK et al. Randomized phase II trial of docetaxel/irinotecan with or without celecoxib in de second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006; 24: 4825-4832.
22. Groen HJM, Sietsma H, Vincent A et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 2011; 29: 4320-4326.
23. Nugent FW, Mertens WC, Graziano S et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 2005; 48: 267-273.
24. Schneider BJ, Kalemkerian GP, Kraut MJ et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol 2008; 3: 1454-1459.
25. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-515.
26. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
27. Ozols RF, Thigpen JT, Dauplat J et al. Advanced ovarian cancer. Dose intensity. Ann Oncol 1993; 4 (Suppl. 4): 49-56.
28. Lind MJ, Ghazal-Aswad S, Gumbrell L et al. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer. J Clin Oncol 1996; 14: 800-805.
29. Rustin GJ, Van der Burg ME, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.